ABSTRACT
Liposome modification by targeting ligands has been used to mediate specific interactions and drug delivery to target cells. In this study, a new peptide ligand, CP7, was found to be able to effectively bind to FGFR1 through reverse molecular docking and could cooperate with VEGFR3 to achieve targeting of A549 cells. CP7 was modified on the surface of the liposome to construct a targeted and safe nanovehicle for the delivery of a therapeutic gene, Mcl-1 siRNA. Due to the specific binding between CP7 and A549 cells, siRNA-loaded liposome-PEG-CP7 showed increased cellular uptake in vitro, resulting in significant apoptosis of tumor cells through silencing of the Mcl-1 gene, which is associated with apoptosis and angiogenesis. This gene delivery system also showed significantly better antitumor activity in tumor-bearing mice in vivo. All of these suggested that siRNA-loaded liposome-PEG-CP7 could be a promising gene drug delivery system with good bioavailability and minimal side effects for treatment.
Subject(s)
Liposomes , Lung Neoplasms , Animals , Cell Line, Tumor , Drug Delivery Systems/methods , Liposomes/chemistry , Lung Neoplasms/genetics , Lung Neoplasms/therapy , Mice , Molecular Docking Simulation , Myeloid Cell Leukemia Sequence 1 Protein , Peptides/chemistry , Peptides/genetics , RNA, Small Interfering/metabolismABSTRACT
BACKGROUND: According to data estimated by the WHO, primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of death around the world. Hepatocellular carcinoma (HCC) is one of the most common primary liver malignancies, so effective therapy is highly desired for HCC. RESULTS: In this study, the use of poly(L-Aspartic acid)-poly(ethylene glycol)/combretastatin A4 (CA4-NPs) was aimed to significantly disrupt new blood vessels in tumor tissues for targeted hepatic tumor therapy. Here, PEG-b-PAsp-g-CA4 showed significantly prolonged retention in plasma and tumor tissue. Most importantly, CA4-NPs were mainly distributed at the tumor site because of the triple target effects-enhanced permeability and retention (EPR) effect, acid-sensitive (pH = 5.5) effect to the tumor microenvironment (TME), and good selectivity of CA4 for central tumor blood vessel. Considering that CA4-NPs might induce severe hypoxic conditions resulting in high expression of HIF-1α in tumor tissues, which could induce the overexpression of PD-L1, herein we also used a programmed death-ligand 1 antibody (aPD-L1) to prevent immunosuppression. This way of complementary combination is able to achieve an ideal treatment effect in tumor site where CA4-NPs and aPD-L1 could respond to the inner area and peripheral area, respectively. As a result, a significant decrease in tumor volume and weight was observed in the combination group of CA4-NPs plus aPD-L1 compared with CA4-NPs or aPD-L1 monotherapy in subcutaneous Hepa1-6 hepatic tumor models. CONCLUSIONS: We presented a new idea that co-administration of CA4-NPs and aPD-L1 possessed notable anti-tumor efficacy for HCC treatment.
Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antineoplastic Agents/pharmacology , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Nanoparticles/administration & dosage , Stilbenes/administration & dosage , Animals , Antibodies, Monoclonal, Humanized/chemistry , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , B7-H1 Antigen , Carcinoma, Hepatocellular/pathology , Disease Models, Animal , Drug Synergism , Female , Humans , Liver Neoplasms/pathology , Mice , Mice, Inbred C57BL , Nanoparticles/chemistry , Polyethylene Glycols , Stilbenes/chemistry , Tumor Microenvironment/drug effectsABSTRACT
The tremendous development of peptide-based cancer vaccine has attracted incremental interest as a powerful approach in cancer management, prevention and treatment. As successful as tumor vaccine has been, major challenges associated with achieving efficient immune response against cancer are (1) drainage to and retention in lymph nodes; (2) uptake by dendritic cells (DCs); (3) activation of DCs. In order to overcome these barriers, here we construct PBE-modified TRP2 nanovaccine, which comprises TRP2 peptide tumor antigen and diblock copolymer PEG-b-PAsp grafted with phenylboronic ester (PBE). We confirmed that this TRP2 nanovaccine can be effectively trapped into lymph node, uptake by dendritic cells and induce DC maturation, relying on increased negative charge, ROS response and pH response. Consistently, this vehicle loaded with TRP2 peptide could boost the strongest T cell immune response against melanoma in vivo and potentiate antitumor efficacy both in tumor prevention and tumor treatment without any exogenous adjuvant. Furthermore, the TRP2 nanovaccine can suppress the tumor growth and prolong animal survival time, which may result from its synergistic effect of inhibiting tumor immunosuppression and increasing cytotoxic lymphocyte (CTL) response. Hence this type of PBE-modified nanovaccine would be widely used as a simple, safe and robust platform to deliver other antigen in cancer immunotherapy.
Subject(s)
Cancer Vaccines , Nanoparticles , Neoplasms , Animals , Antigens , Dendritic Cells , Esters , Immunotherapy , Membrane Proteins , Neoplasms/drug therapy , Peptide Fragments , Polymers/pharmacologyABSTRACT
The size-uniformed mesoporous Ag@SiO2 nanospheres' catalysts were prepared in one-pot step via reducing AgNO3 by different types of aldehyde, which could control the size of Ag@SiO2 NPs and exhibit excellent catalytic activity for the hydrogenation of nitrobenzene. The results showed that the Ag core size, monitored by different aldehydes with different reducing abilities, together with the ideal monodisperse core-shell mesoporous structure, was quite important to affect its superior catalytic performances. Moreover, the stability of Ag fixed in the core during reaction for 6 h under 2.0 MPa, 140 °C made this type of Ag@SiO2 catalyst separable and environmentally friendly compared with those conventional homogeneous catalysts and metal NPs catalysts. The best catalyst with smaller Ag cores was prepared by strong reducing agents such as CH2O. The conversion of nitrobenzene can reach 99.9%, the selectivity was 100% and the catalyst maintained its activity after several cycles, and thus, it is a useful novel candidate for the production of aniline.